Skip to main content

Biologics Safety Testing Market To Reach USD 4.90 Billion By 2022 : Increasing Pharmaceutical Outsourcing

 What This Report Will Provide?

Biologics are pharmaceutical products that are extracted from biological sources. Biologics safety testing is carried out by manufacturers to detect contaminants like bacterial toxins, mycoplasma, and viruses. It is a mandatory process in these companies for the quality control of raw materials as well as for process control and validation of end products.

Expected Revenue Growth:

The global biologics safety testing market is expected to reach USD 4.90 Billion by 2022 from USD 2.75 Billion in 2017, at a CAGR of 12.2% during forecast period.


Major Growth Boosters:

The major factors driving the growth of this market are the growth in pharmaceutical & biotechnology industry driven by government support, the positive trend of R&D investment in the life science sector, increasing number of drug launches, and high incidence & large economic burden of chronic diseases. In the coming years, emerging markets and increasing pharmaceutical outsourcing are expected to offer growth opportunities for players in the biologics safety testing market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=34624144

By application, Vaccine and Therapeutics Development segment to record the highest CAGR during the forecast period

Vaccine and Therapeutics Development segment is projected to register a higher CAGR during the forecast period. Factors such as the rising prevalence of diseases, increasing initiatives for immunization, and increasing company investments in vaccine development are expected to drive the growth of this market segment.

Critical questions the report answers:

  • Where will all these developments take the industry in the long term?
  • What are the upcoming trends for the biologics safety testing market?
  • Which segment provides the most opportunity for growth?
  • Who are the leading vendors operating in this market?
  • What are the opportunities for new market entrants?

Request Sample Report:   https://www.marketsandmarkets.com/requestsampleNew.asp?id=34624144 

Growth in pharmaceutical and biotechnology industries driven by government support

Pharmaceutical and biotechnology companies are the largest end users in the biologics safety testing market. Biologics safety testing is carried out at all levels of manufacturing to minimize the risk of product contamination in these industries. According to the International Trade Administration, the global pharmaceuticals market is projected to grow from USD 1 trillion in 2015 to USD 1.3 trillion by 2020, at a CAGR of 4.9%.

Regional Growth Analysis:

North America is expected to account for the largest share of this market. The strong R&D trend in life sciences and growth in pharmaceutical industries will drive the biologics safety testing market in the North American region.

Labels:

Comments

Post a Comment

Popular posts from this blog

Medical Device Reprocessing Market – Statistics and Growth Dynamics To 2022

  Expected Revenue Growth: The  global medical device reprocessing market  is projected to be valued at USD 823.5 Million in 2017 and is expected to grow at a CAGR of 16.3% during the forecast period to reach to USD 1,754 Million by 2022. Base year considered for the report is 2016. What This Report Will Provide? The growth of this market is majorly driven by the increased utilization of the low priced reprocessed medical devices as compared to new devices, increased efforts towards reducing regulated medical waste (RMW), and rising number of surgical procedures associated with the growing prevalence of chronic diseases. However, the risk of transmission of surgical site infections associated with the use of reprocessed devices may hinder the growth of the market to a certain extent. Major Growth Boosters: The medical device reprocessing includes cleaning, disinfection, inspection, sterilization, and repackaging of used medical devices for its reuse to diagnose and treat ...
Post a Comment
Read more

Aesthetic/Cosmetic Lasers Market Worth USD 1,132.7 Million (At A CAGR Of 10.2%)

  Increasing preference for noninvasive cosmetic procedures, increasing disposable income, technological advancements, and rising medical tourism are the major drivers of the aesthetic lasers market. However, lack of reimbursement will restrain the growth of this market. What This Report Will Provide? Factors such as multiplatform lasers provide clinicians the flexibility and versatility of several standalone systems in a single package, and provide combination therapy to synergistically treat a single indication or provide treatment addressing multiple elements of any indication is contributing to the high growth of this segment in the forecast period. Expected Revenue Growth: The global  aesthetic lasers market  is estimated to grow at a CAGR of 10.2% during the forecast period, to reach USD 1,132.7 Million by 2021. Major Growth Boosters: Growing adoption of noninvasive procedures, changing lifestyles, rising incidence of skin damage, reduction in procedural costs, and ...
Post a Comment
Read more

Autoinjectors Market | Newest Industry Data, Future Trends and Forecast 2023

Autoinjectors are used to self-administer drugs for the treatment of various diseases and conditions, such as rheumatoid arthritis, multiple sclerosis, diabetes, and anaphylaxis. Autoinjectors are easy to use, portable, and improve dosing accuracy, making them one of the most popular methods for the self-administration of drugs. The  global autoinjectors market  is projected to reach USD 85.31 billion by 2023 from an estimated USD 28.91 billion in 2018, at a CAGR of 24.2% during the forecast period (2018-2023). In terms of Therapy, the global autoinjectors market can be segmented into: Rheumatoid Arthritis Multiple Sclerosis Diabetes Anaphylaxis Other Therapies (Cardiovascular Diseases, Migraines, Psoriasis, and Anemia) By therapy, the rheumatoid arthritis segment is expected to account for the largest share of the market in 2018 On the basis of therapy, the autoinjectors market is segmented into rheumatoid arthritis, multiple sclerosis, diabetes, anaphylaxis, and other therap...
Post a Comment
Read more